Compare Eli Lilly And Co (LLY) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Strategy Inc. — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Strategy Inc. trades at $154.34 (market cap $60.40B). The key difference: Eli Lilly And Co is far larger — about 17.2× Strategy Inc.'s market cap, and Eli Lilly And Co pays a 0.59% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Strategy Inc. for 112 Days on average.
| LLY | MSTR | |
|---|---|---|
Market Cap | $1.04T | $60.40B |
Volume | 3,064,878 | 23,421,830 |
Sector | Health | Technology |
52-Week High | $1.28K | $320.29 |
52-Week Low | $799.57 | $82.31 |
Typical Hold Time | 93 Days | 112 Days |
Enterprise Value | $1.09T | $79.16B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
MSTR stock trades at $154.34, up 0.63% with a bullish technical signal and strong analyst support. The company shows concerning fundamentals with negative net income margins of -6,102.96% and three consecutive earnings misses, though revenue remains stable around $477 million. Recent news highlights Citigroup's upgraded price target to $240 and the stock's 35% monthly surge, positioning it as a high-risk, high-reward play tied to Bitcoin market movements despite operational challenges.
Outlook remains polarized: 62% analyst buy ratings and a $253 consensus target suggest 64% upside, but extreme profitability risks and volatile cash flows demand caution. Investment opportunity hinges on Bitcoin's performance amplifying equity value, while risks include persistent losses, debt burden, and sensitivity to crypto market swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
